EMMA News and Press, Emmaus Life Sciences Incorporation From 04/15/24

Emmaus Life Sciences Reports Delayed Filing of Annual Report PR Newswire TORRANCE, Calif. , April 15, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disea...

China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...

Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico PR Newswire TORRANCE, Calif. , Feb. 2, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received m...

2023-11-14 10:04:36 ET More on Emmaus Life Sciences Emmaus Life Sciences says Yutaka Niihara to step down as CEO Financial information for Emmaus Life Sciences For further details see: Emmaus Life Sciences GAAP EPS of -$0.01, revenue of $5M

Emmaus Life Sciences Reports Q3 2023 Financial Results PR Newswire TORRANCE, Calif. , Nov. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Emmaus Life Sciences Incorporation (EMMA) is expected to report for Q1 2024

2023-08-23 11:58:34 ET More on Emmaus Life Sciences Emmaus sickle cell disease therapy Endari to get added to Florida Preferred Drug List Emmaus Life Sciences' Endari gets approval in UAE for sickle cell disease Emmaus Life Sciences inks agreement with Asembia ...

Emmaus Life Sciences Reports Management Changes PR Newswire Principal Inventor of Endari® (L-glutamine oral powder) and Long-time Chairman and Chief Executive Officer Free to Purse New Projects Company Appoints Interim Co-Presidents to Focus on Core Business ...

2023-08-14 17:28:16 ET Emmaus Life Sciences press release ( OTCQX:EMMA ): Q2 GAAP EPS of -$0.03. Revenue of $10.8M (+152.3% Y/Y). For further details see: Emmaus Life Sciences GAAP EPS of -$0.03, revenue of $10.8M